
Laura Pyle developed and maintained the CHCO-Code repository, delivering robust analytics pipelines for clinical and omics data integration, longitudinal modeling, and reproducible reporting. She engineered end-to-end workflows in R and R Markdown, emphasizing data harmonization, mixed-effects modeling, and scalable visualization to support metabolic and biomarker research. Her work included implementing user-specific data environments, automating data ingestion, and optimizing statistical analyses for risk stratification and outcome prediction. By refactoring code, standardizing path handling, and enhancing documentation, Laura improved maintainability and collaboration. The depth of her engineering enabled faster, more reliable insights for clinical decision support and cross-study analytics.
April 2026 (2026-04) - Maintained CHCO-Code repository by performing a targeted cleanup of R Markdown files related to the T1-DISCO project to streamline the repository structure. No user-facing functionality changes were made. The effort improves maintainability, reduces onboarding friction, and sets a clean baseline for future work. Commit reference: 2142d49a4d161e9dc7be31186400bc2dfe4bae80 (move T1DISCO files).
April 2026 (2026-04) - Maintained CHCO-Code repository by performing a targeted cleanup of R Markdown files related to the T1-DISCO project to streamline the repository structure. No user-facing functionality changes were made. The effort improves maintainability, reduces onboarding friction, and sets a clean baseline for future work. Commit reference: 2142d49a4d161e9dc7be31186400bc2dfe4bae80 (move T1DISCO files).
March 2026 CHCO-Code monthly summary (childhealthbiostatscore/CHCO-Code). Delivered analytics enhancements that strengthen metabolic health risk assessment and streamline data processing, enabling faster insights for clinical decision support.
March 2026 CHCO-Code monthly summary (childhealthbiostatscore/CHCO-Code). Delivered analytics enhancements that strengthen metabolic health risk assessment and streamline data processing, enabling faster insights for clinical decision support.
February 2026 — CHCO-Code monthly summary: Delivered key features with strong business value and robust technical improvements. Implemented a new R-based clinical data analysis tooling with Body Surface Area (BSA) calculation and lipid data processing/reporting capabilities, including visualization script and lipid descriptors. Enhanced data loading paths and environment compatibility to support multi-user access and updated directory structures. These changes improve clinical insights turnaround, reporting reliability, and collaboration onboarding, while demonstrating proficiency in R analytics, data visualization, and cross-environment deployment.
February 2026 — CHCO-Code monthly summary: Delivered key features with strong business value and robust technical improvements. Implemented a new R-based clinical data analysis tooling with Body Surface Area (BSA) calculation and lipid data processing/reporting capabilities, including visualization script and lipid descriptors. Enhanced data loading paths and environment compatibility to support multi-user access and updated directory structures. These changes improve clinical insights turnaround, reporting reliability, and collaboration onboarding, while demonstrating proficiency in R analytics, data visualization, and cross-environment deployment.
December 2025 (CHCO-Code) focused on delivering scalable, reproducible analytics through per-user data environments, enhanced visualization, longitudinal analysis readiness, and ComptoxAI integration. These changes isolate workspaces, expand analytical capabilities, and extend biomarker support, enabling faster, safer experimentation and deeper insights into glycemia–proteomics relationships.
December 2025 (CHCO-Code) focused on delivering scalable, reproducible analytics through per-user data environments, enhanced visualization, longitudinal analysis readiness, and ComptoxAI integration. These changes isolate workspaces, expand analytical capabilities, and extend biomarker support, enabling faster, safer experimentation and deeper insights into glycemia–proteomics relationships.
November 2025 was a productive month focused on delivering scalable data pipelines, robust analyses, and reproducible reporting across metabolic, safety, and clinical data domains for CHCO-Code. Key features delivered include urine metabolomics data integration and modeling, Type 1 Diabetes risk-group simulations with power analysis, and DSMB safety data reporting documentation. In addition, improvements to EDIPE analysis and clinical data QA enhanced data quality and consistency. These efforts produced ready-to-share outputs (Rmds, qmds, and CSV exports) and established groundwork for broader adoption across projects. Technologies leveraged included R, R Markdown, and standardized data workflows, demonstrating strong data manipulation, statistical modeling, and documentation skills with a clear business value in faster insight generation and higher data reliability.
November 2025 was a productive month focused on delivering scalable data pipelines, robust analyses, and reproducible reporting across metabolic, safety, and clinical data domains for CHCO-Code. Key features delivered include urine metabolomics data integration and modeling, Type 1 Diabetes risk-group simulations with power analysis, and DSMB safety data reporting documentation. In addition, improvements to EDIPE analysis and clinical data QA enhanced data quality and consistency. These efforts produced ready-to-share outputs (Rmds, qmds, and CSV exports) and established groundwork for broader adoption across projects. Technologies leveraged included R, R Markdown, and standardized data workflows, demonstrating strong data manipulation, statistical modeling, and documentation skills with a clear business value in faster insight generation and higher data reliability.
October 2025 CHCO-Code monthly summary: Delivered key data preparation, modeling, and analysis enhancements with measurable business impact. Implemented path handling standardization, expanded adiposity and metabolic modeling with NEBULA integration and elastic net support, introduced baseline-adjusted insulin sensitivity analysis, and advanced NEBULA-based method comparisons. Improved data quality and reproducibility with retinopathy dataset updates and new metrics (bmipct), plus automated sample pulling and EDIPE analysis. Fixed critical typos and power calculation bugs to ensure correct results. These efforts enabled more accurate analyses, faster reporting, and scalable analytics for metabolic and ophthalmologic study pipelines.
October 2025 CHCO-Code monthly summary: Delivered key data preparation, modeling, and analysis enhancements with measurable business impact. Implemented path handling standardization, expanded adiposity and metabolic modeling with NEBULA integration and elastic net support, introduced baseline-adjusted insulin sensitivity analysis, and advanced NEBULA-based method comparisons. Improved data quality and reproducibility with retinopathy dataset updates and new metrics (bmipct), plus automated sample pulling and EDIPE analysis. Fixed critical typos and power calculation bugs to ensure correct results. These efforts enabled more accurate analyses, faster reporting, and scalable analytics for metabolic and ophthalmologic study pipelines.
Summary for 2025-09: CHCO-Code delivered substantial business value through data pipeline stabilization, expanded survival/progression modeling, and enhanced reporting. The month focused on strengthening data access, automating biomarker handling, integrating advanced analyses, and producing stakeholder-ready outputs with robust visuals. Key design and programmatic improvements reduced manual work, improved data quality, and accelerated time-to-insight across studies. Key features delivered: - CKM Integrated Longitudinal Analysis Update to longitudinal.qmd, improving longitudinal workflow and insights for ongoing studies. - Biomarker Extraction and NA Handling automation to ensure complete data for downstream analyses. - Data Infrastructure: Paths Setup to establish and refine reliable data access and processing pipelines. - Progression Variable Enhancements and Expanded modeling capabilities (including Cox models) for more robust survival/progression analyses. - Descriptive Tables Development and CKM reporting enhancements to streamline reporting and stakeholder communications. Major bugs fixed and stability improvements: - Code cleanup and readability refinements. - Reversion of a column name fix to preserve prior behavior where necessary. - Exclusion of BMI-related analyses to maintain focus on core outcomes. - Plotting and figure handling fixes, including missing figure remediation. - Updates to simulation and cohort scripts (Splatter-related and cohort utilities) to improve reliability. Overall impact and accomplishments: - Faster, reproducible analytical cycles with cleaner, well-documented code. - Broader analytical capabilities (elastic net with covariates, proteomics deltas, FGSEA/GSEA tooling). - Improved reporting cadence with ready-to-share CKM figures and descriptive tables, enabling faster business decisions. Technologies/skills demonstrated: - R-based survival analysis (Cox models), elastic net modeling, time-to-event analyses. - Proteomics integration and delta calculations, FGSEA/GSEA tooling, Splatter-based simulations. - Data engineering practices: pipeline paths, reproducible reporting with gtsummary equivalents. - Strong version control discipline and collaboration across data science and analytics teams.
Summary for 2025-09: CHCO-Code delivered substantial business value through data pipeline stabilization, expanded survival/progression modeling, and enhanced reporting. The month focused on strengthening data access, automating biomarker handling, integrating advanced analyses, and producing stakeholder-ready outputs with robust visuals. Key design and programmatic improvements reduced manual work, improved data quality, and accelerated time-to-insight across studies. Key features delivered: - CKM Integrated Longitudinal Analysis Update to longitudinal.qmd, improving longitudinal workflow and insights for ongoing studies. - Biomarker Extraction and NA Handling automation to ensure complete data for downstream analyses. - Data Infrastructure: Paths Setup to establish and refine reliable data access and processing pipelines. - Progression Variable Enhancements and Expanded modeling capabilities (including Cox models) for more robust survival/progression analyses. - Descriptive Tables Development and CKM reporting enhancements to streamline reporting and stakeholder communications. Major bugs fixed and stability improvements: - Code cleanup and readability refinements. - Reversion of a column name fix to preserve prior behavior where necessary. - Exclusion of BMI-related analyses to maintain focus on core outcomes. - Plotting and figure handling fixes, including missing figure remediation. - Updates to simulation and cohort scripts (Splatter-related and cohort utilities) to improve reliability. Overall impact and accomplishments: - Faster, reproducible analytical cycles with cleaner, well-documented code. - Broader analytical capabilities (elastic net with covariates, proteomics deltas, FGSEA/GSEA tooling). - Improved reporting cadence with ready-to-share CKM figures and descriptive tables, enabling faster business decisions. Technologies/skills demonstrated: - R-based survival analysis (Cox models), elastic net modeling, time-to-event analyses. - Proteomics integration and delta calculations, FGSEA/GSEA tooling, Splatter-based simulations. - Data engineering practices: pipeline paths, reproducible reporting with gtsummary equivalents. - Strong version control discipline and collaboration across data science and analytics teams.
August 2025 (CHCO-Code) delivered a set of targeted enhancements, cleanups, and CKM-focused capabilities to improve data quality, pipeline reliability, and end-to-end analytics. Key work included function-based user/path handling, pipeline simplifications, metadata enrichment for downstream reporting, and expanded CKM/QMD tooling. The month also advanced BMI association analysis, descriptive reporting, and QA/documentation practices to support faster iteration and better stakeholder visibility.
August 2025 (CHCO-Code) delivered a set of targeted enhancements, cleanups, and CKM-focused capabilities to improve data quality, pipeline reliability, and end-to-end analytics. Key work included function-based user/path handling, pipeline simplifications, metadata enrichment for downstream reporting, and expanded CKM/QMD tooling. The month also advanced BMI association analysis, descriptive reporting, and QA/documentation practices to support faster iteration and better stakeholder visibility.
July 2025 monthly performance summary for CHCO-Code (childhealthbiostatscore). Delivered end-to-end data handling, robust randomization framework, and foundational modeling work with a focus on reproducibility and business value. Fixed key data integrity issues to ensure reliable downstream analyses, and enhanced documentation and templates to accelerate future analyses and reporting.
July 2025 monthly performance summary for CHCO-Code (childhealthbiostatscore). Delivered end-to-end data handling, robust randomization framework, and foundational modeling work with a focus on reproducibility and business value. Fixed key data integrity issues to ensure reliable downstream analyses, and enhanced documentation and templates to accelerate future analyses and reporting.
June 2025 — CHCO-Code monthly summary: Delivered major features to broaden proteomics and single-cell analysis workflows, improved code organization and data handling, and strengthened modeling capabilities. The month focused on expanding urine proteomics scaffolding, enhancing scRNA-seq simulation tooling, and implementing robust plotting/merge fixes to improve reliability for downstream analyses and reporting. Strengthened data ingestion and variable support (TODAY/TODAY2, visit days) and advanced statistical modeling (predictors, mixed effects) to enable more accurate, scalable analyses across projects.
June 2025 — CHCO-Code monthly summary: Delivered major features to broaden proteomics and single-cell analysis workflows, improved code organization and data handling, and strengthened modeling capabilities. The month focused on expanding urine proteomics scaffolding, enhancing scRNA-seq simulation tooling, and implementing robust plotting/merge fixes to improve reliability for downstream analyses and reporting. Strengthened data ingestion and variable support (TODAY/TODAY2, visit days) and advanced statistical modeling (predictors, mixed effects) to enable more accurate, scalable analyses across projects.
May 2025 monthly summary focusing on data platform enhancements, cross-study integration, and reporting readiness within CHCO-Code. Delivered core baseline data preparation, expanded metrics and modeling capabilities, improved event reporting, and enabled cross-cohort analyses. Resolved pipeline issues from library updates to stabilize data processing and reporting.
May 2025 monthly summary focusing on data platform enhancements, cross-study integration, and reporting readiness within CHCO-Code. Delivered core baseline data preparation, expanded metrics and modeling capabilities, improved event reporting, and enabled cross-cohort analyses. Resolved pipeline issues from library updates to stabilize data processing and reporting.
April 2025 monthly summary for CHCO-Code: Delivered end-to-end analytics enhancements, reproducible pipelines, and reporting artifacts that strengthen clinical and imaging data insights and accelerate decision-making.
April 2025 monthly summary for CHCO-Code: Delivered end-to-end analytics enhancements, reproducible pipelines, and reporting artifacts that strengthen clinical and imaging data insights and accelerate decision-making.
March 2025 monthly summary for childhealthbiostatscore/CHCO-Code. Focused on delivering core analytics capabilities, improving data reliability, and cleaning the codebase for maintainability and faster iteration: Key features delivered - Data Preparation Enhancements: added dummy MRN to PB90.R; cleanup of legacy code and path corrections to stabilize data prep pipelines. Representative commits: df71b58d..., b12847d2..., cdce0e95..., 1634005e..., fde86a53..., 390b599a... - TODAY adenine echo analysis and related cleanup: created TODAY adenine echo report (TODAY adenine echo.Rmd) and removed correlations with TODAY2 echo to reduce noise. Commit: bfac2eb001e52a53... - Tyler regression check and related analyses: introduced Tyler regression check script to validate model assumptions. Commit: d4435a535ca3... - Randomization and trajectories reporting: added randomization script and trajectories report to support trial design analyses. Commits: 868f28de..., 667f91d5... - Corrplot improvements and related updates: updated corrplot implementation and removed obsolete function; introduced targeted FGSEA version and path-related updates. Commits: 8894c42f0098..., 6971a4aea... Major bugs fixed - FGSEA code fix to stabilize enrichment analyses (commit: 5f67700b6f72...) - PEDSQL scoring fix to correct scoring calculations (commit: 8d7e8682decb...) - Remove OSA proteins from dataset across multiple commits (commits: ce68fb4571..., bcb8cb00f0..., efb385ea3f..., 0b874cc02...). Overall impact and accomplishments - Improved data preparation reliability and reproducibility, enabling faster, cleaner downstream analyses and reporting. - Stabilized key analytics pipelines (FGSEA, PEDSQL) and reduced data noise by removing nonessential components (PWV analyses, OSA proteins). - Created reusable analytic assets (TODAY echo report, Tyler regression script, randomization and trajectories reports) that accelerate future studies and evidence generation. Technologies/skills demonstrated - R and R Markdown (Rmd) for report generation and reproducible research - Data wrangling and pipeline cleanup, codebase refactoring for path handling and legacy code removal - Statistical methods: FGSEA, regression diagnostics, correlation analyses - Visualization: corrplot improvements - Version control discipline and traceability with descriptive commits and feature-focused branches Business value - Faster turnaround for exploratory analyses and reporting - Reduced risk of data misinterpretation through cleaned, auditable pipelines - Greater confidence in model results and reproducibility for stakeholders
March 2025 monthly summary for childhealthbiostatscore/CHCO-Code. Focused on delivering core analytics capabilities, improving data reliability, and cleaning the codebase for maintainability and faster iteration: Key features delivered - Data Preparation Enhancements: added dummy MRN to PB90.R; cleanup of legacy code and path corrections to stabilize data prep pipelines. Representative commits: df71b58d..., b12847d2..., cdce0e95..., 1634005e..., fde86a53..., 390b599a... - TODAY adenine echo analysis and related cleanup: created TODAY adenine echo report (TODAY adenine echo.Rmd) and removed correlations with TODAY2 echo to reduce noise. Commit: bfac2eb001e52a53... - Tyler regression check and related analyses: introduced Tyler regression check script to validate model assumptions. Commit: d4435a535ca3... - Randomization and trajectories reporting: added randomization script and trajectories report to support trial design analyses. Commits: 868f28de..., 667f91d5... - Corrplot improvements and related updates: updated corrplot implementation and removed obsolete function; introduced targeted FGSEA version and path-related updates. Commits: 8894c42f0098..., 6971a4aea... Major bugs fixed - FGSEA code fix to stabilize enrichment analyses (commit: 5f67700b6f72...) - PEDSQL scoring fix to correct scoring calculations (commit: 8d7e8682decb...) - Remove OSA proteins from dataset across multiple commits (commits: ce68fb4571..., bcb8cb00f0..., efb385ea3f..., 0b874cc02...). Overall impact and accomplishments - Improved data preparation reliability and reproducibility, enabling faster, cleaner downstream analyses and reporting. - Stabilized key analytics pipelines (FGSEA, PEDSQL) and reduced data noise by removing nonessential components (PWV analyses, OSA proteins). - Created reusable analytic assets (TODAY echo report, Tyler regression script, randomization and trajectories reports) that accelerate future studies and evidence generation. Technologies/skills demonstrated - R and R Markdown (Rmd) for report generation and reproducible research - Data wrangling and pipeline cleanup, codebase refactoring for path handling and legacy code removal - Statistical methods: FGSEA, regression diagnostics, correlation analyses - Visualization: corrplot improvements - Version control discipline and traceability with descriptive commits and feature-focused branches Business value - Faster turnaround for exploratory analyses and reporting - Reduced risk of data misinterpretation through cleaned, auditable pipelines - Greater confidence in model results and reproducibility for stakeholders
February 2025 monthly summary for CHCO-Code focused on delivering end-to-end analytics enhancements that improve clinical omics insights, data pipeline readability, and reporting readiness. The work emphasizes business value by enabling more robust pre-/post-operative pathway analyses, expanding longitudinal data coverage, and strengthening statistical reporting for manuscript-ready results.
February 2025 monthly summary for CHCO-Code focused on delivering end-to-end analytics enhancements that improve clinical omics insights, data pipeline readability, and reporting readiness. The work emphasizes business value by enabling more robust pre-/post-operative pathway analyses, expanding longitudinal data coverage, and strengthening statistical reporting for manuscript-ready results.
January 2025 monthly summary for CHCO-Code (childhealthbiostatscore). Delivered cross-functional analytics improvements and reporting capability that directly support collaboration, reproducibility, and data-driven decision making across TODAY and Teen-LABS. All work aligns with the CHCO-Code repository scope and data governance standards.
January 2025 monthly summary for CHCO-Code (childhealthbiostatscore). Delivered cross-functional analytics improvements and reporting capability that directly support collaboration, reproducibility, and data-driven decision making across TODAY and Teen-LABS. All work aligns with the CHCO-Code repository scope and data governance standards.
December 2024 performance summary for CHCO-Code (childhealthbiostatscore). Delivered end-to-end data curation, advanced analytics, omics integration, and expanded reporting with a focus on data quality, reproducibility, and business impact. Achievements include data cleaning and demographics enhancement with PRL; delta-based, mixed BP–protein modeling; omics reporting integration (proteomics/HTN Somascan; KPMP recruitment labs; IMPROVE transcriptomics); visualization improvements for SBP/DBP and figure styling; and a broad reporting/governance expansion (SCH market share, US Census, WA OFM, anchor stream size). Also implemented diabetes duration tracking, enhanced path handling, unique IDs generation, and a targeted code cleanup to reduce technical debt. These efforts improve data quality for risk stratification, accelerate reporting cycles, and provide stronger foundation for data-driven decisions.
December 2024 performance summary for CHCO-Code (childhealthbiostatscore). Delivered end-to-end data curation, advanced analytics, omics integration, and expanded reporting with a focus on data quality, reproducibility, and business impact. Achievements include data cleaning and demographics enhancement with PRL; delta-based, mixed BP–protein modeling; omics reporting integration (proteomics/HTN Somascan; KPMP recruitment labs; IMPROVE transcriptomics); visualization improvements for SBP/DBP and figure styling; and a broad reporting/governance expansion (SCH market share, US Census, WA OFM, anchor stream size). Also implemented diabetes duration tracking, enhanced path handling, unique IDs generation, and a targeted code cleanup to reduce technical debt. These efforts improve data quality for risk stratification, accelerate reporting cycles, and provide stronger foundation for data-driven decisions.
November 2024 performance summary for CHCO-Code: End-to-end data loading, integration, and preparation across IMPROVE and TL studies; production of descriptive reporting for manuscripts; advanced analyses and visualization; and targeted bug fixes that improved reliability, reproducibility, and cross-study harmonization, delivering tangible business value of faster manuscript readiness and robust analytics.
November 2024 performance summary for CHCO-Code: End-to-end data loading, integration, and preparation across IMPROVE and TL studies; production of descriptive reporting for manuscripts; advanced analyses and visualization; and targeted bug fixes that improved reliability, reproducibility, and cross-study harmonization, delivering tangible business value of faster manuscript readiness and robust analytics.
October 2024 (2024-10) monthly summary for CHCO-Code development focusing on delivering a robust analytics framework, extending biometrics and transcriptomic capabilities, and improving data quality. Key features rolled out include a Teen-LABS BMI analysis framework with data cleaning, longitudinal mixed-effects modeling, mid-intervention metrics, volcano plot visualization, adjusted p-values, and export-heavy Excel reporting; a new UACR mg/g calculation with updated summary statistics for a more precise albuminuria measure; eGFR calculation using creatinine and cystatin C with updated data summaries; a dedicated scRNA-seq differential expression analysis script implementing mixed-effects modeling and careful p-value handling. Alongside features, a data integrity and adherence metrics bug fix addressed duplicate lab entries and refined adherence calculations, and a cleanup of temporary RData files reduced repository clutter. Commit activity demonstrates a strong emphasis on reproducibility, data quality, and scalable reporting. Business value includes more accurate pediatric biometrics and kidney function analytics, improved data hygiene reducing downstream analysis errors, and enhanced reporting pipelines for stakeholders.
October 2024 (2024-10) monthly summary for CHCO-Code development focusing on delivering a robust analytics framework, extending biometrics and transcriptomic capabilities, and improving data quality. Key features rolled out include a Teen-LABS BMI analysis framework with data cleaning, longitudinal mixed-effects modeling, mid-intervention metrics, volcano plot visualization, adjusted p-values, and export-heavy Excel reporting; a new UACR mg/g calculation with updated summary statistics for a more precise albuminuria measure; eGFR calculation using creatinine and cystatin C with updated data summaries; a dedicated scRNA-seq differential expression analysis script implementing mixed-effects modeling and careful p-value handling. Alongside features, a data integrity and adherence metrics bug fix addressed duplicate lab entries and refined adherence calculations, and a cleanup of temporary RData files reduced repository clutter. Commit activity demonstrates a strong emphasis on reproducibility, data quality, and scalable reporting. Business value includes more accurate pediatric biometrics and kidney function analytics, improved data hygiene reducing downstream analysis errors, and enhanced reporting pipelines for stakeholders.

Overview of all repositories you've contributed to across your timeline